

Income statement

Three months ended 31st March 2011

	Results before major restructuring £m	Major restructuring £m	Total £m	Results before major restructuring \$m	Major restructuring \$m	Total \$m
TURNOVER	6,585	-	6,585	10,536	-	10,536
Cost of sales	(1,780)	(15)	(1,795)	(2,848)	(24)	(2,872)
Gross profit	4,805	(15)	4,790	7,688	(24)	7,664
Selling, general and administration	(2,054)	(103)	(2,157)	(3,286)	(165)	(3,451)
Research and development	(898)	(17)	(915)	(1,437)	(27)	(1,464)
Other operating income	317	-	317	507	-	507
OPERATING PROFIT	2,170	(135)	2,035	3,472	(216)	3,256
Finance income	19	-	19	30	-	30
Finance expense	(193)	-	(193)	(309)	-	(309)
Profit on disposal of interest in associate	584	-	584	934	-	934
Share of after tax profits of associates and joint ventures	19	-	19	31	-	31
PROFIT BEFORE TAXATION	2,599	(135)	2,464	4,158	(216)	3,942
Taxation	(901)	21	(880)	(1,441)	33	(1,408)
PROFIT AFTER TAXATION FOR THE PERIOD	1,698	(114)	1,584	2,717	(183)	2,534
Profit attributable to non-controlling interests	59	-	59	95	-	95
Profit attributable to shareholders	1,639	(114)	1,525	2,622	(183)	2,439
	1,698	(114)	1,584	2,717	(183)	2,534
EARNINGS PER SHARE	32.2p		30.0p	51.5¢		48.0¢
Diluted earnings per share	31.9p		29.6p	51.0¢		47.4¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

Turnover

Pharmaceuticals - Three months ended 31st March 2011

	Total £m	USA £m	Europe £m	Emerging Markets £m	ROW £m	Total \$m	USA \$m	Europe \$m	Emerging Markets \$m	ROW \$m
Respiratory	1,815	791	537	150	337	2,904	1,266	859	240	539
<i>Avamys/Veramyst</i>	72	15	16	7	34	115	24	26	11	54
<i>Flixonase/Flonase</i>	48	3	9	9	27	77	5	14	15	43
<i>Flixotide/Flovent</i>	202	107	40	13	42	323	171	64	21	67
<i>Seretide/Advair</i>	1,223	586	399	76	162	1,957	938	638	122	259
<i>Serevent</i>	52	21	22	1	8	83	33	35	2	13
<i>Ventolin</i>	146	56	36	30	24	234	90	58	48	38
<i>Xyzal</i>	15	-	-	1	14	24	-	-	2	22
<i>Zyrtec</i>	31	-	-	5	26	50	-	-	8	42
Anti-virals	201	41	20	52	88	322	66	32	83	141
<i>Hepsera</i>	28	-	-	12	16	45	-	-	19	26
<i>Relenza</i>	9	-	-	-	9	14	-	-	-	14
<i>Valtrex</i>	90	22	12	6	50	144	35	19	10	80
<i>Zeffix</i>	56	4	6	33	13	90	6	10	53	21
Central nervous system	396	103	120	60	113	633	164	192	96	181
<i>Imigran/Imitrex</i>	51	21	17	2	11	82	34	27	3	18
<i>Keppra</i>	11	-	-	7	4	18	-	-	11	7
<i>Lamictal</i>	114	53	33	14	14	182	85	53	22	22
<i>Requip</i>	53	10	30	-	13	85	16	48	-	21
<i>Seroxat/Paxil</i>	103	1	16	21	65	165	2	25	34	104
<i>Treximet</i>	14	14	-	-	-	22	22	-	-	-
<i>Wellbutrin</i>	19	3	10	4	2	30	5	16	6	3
Cardiovascular and urogenital	615	344	161	35	75	984	550	258	56	120
<i>Arixtra</i>	74	44	24	3	3	118	70	38	5	5
<i>Avodart</i>	166	76	50	9	31	266	122	80	14	50
<i>Coreg</i>	37	37	-	-	-	59	59	-	-	-
<i>Fraxiparine</i>	54	-	39	15	-	86	-	62	24	-
<i>Lovaza</i>	127	126	-	-	1	203	201	-	-	2
<i>Vesicare</i>	28	28	-	-	-	45	45	-	-	-
<i>Volibris</i>	22	-	17	1	4	35	-	27	2	6
Metabolic	91	26	16	17	32	145	42	25	27	51
<i>Avandia products</i>	36	26	-	5	5	58	42	-	8	8
<i>Bonviva/Boniva</i>	16	-	12	1	3	26	-	19	2	5
Anti-bacterials	379	19	156	162	42	606	30	250	259	67
<i>Augmentin</i>	187	3	75	87	22	299	5	120	139	35
Oncology and emesis	150	59	57	14	20	240	94	91	23	32
<i>Arzerra</i>	9	7	3	-	(1)	14	11	5	-	(2)
<i>Hycamtin</i>	14	-	11	2	1	22	-	17	3	2
<i>Promacta</i>	12	6	4	-	2	19	10	6	-	3
<i>Tyverb/Tykerb</i>	52	13	24	6	9	83	21	38	10	14
<i>Votrient</i>	17	12	5	-	-	27	19	8	-	-
Vaccines	758	155	241	178	184	1,213	248	386	285	294
<i>Boostrix</i>	32	15	9	1	7	51	24	14	2	11
<i>Cervarix</i>	109	1	15	10	83	174	2	24	16	132
<i>Fluarix, FluLaval</i>	9	1	-	3	5	14	2	-	5	7
<i>Flu Pandemic</i>	5	-	5	-	-	8	-	8	-	-
<i>Hepatitis</i>	158	70	54	12	22	253	112	87	19	35
<i>Infanrix, Pediarix</i>	161	40	91	12	18	258	64	146	19	29
<i>Rotarix</i>	77	27	10	32	8	123	43	16	51	13
<i>Synflorix</i>	77	-	13	61	3	123	-	21	97	5
Dermatologicals	273	77	62	82	52	437	124	99	131	83
<i>Bactroban</i>	28	11	7	7	3	45	18	11	11	5
<i>Dermovate</i>	19	-	6	6	7	30	-	10	9	11
<i>Duac</i>	28	16	6	3	3	45	25	10	5	5
<i>Soriatane</i>	17	17	-	-	-	27	27	-	-	-
<i>Zovirax</i>	36	11	7	6	12	58	18	11	10	19
Other	233	4	65	91	73	373	6	104	146	117
	4,911	1,619	1,435	841	1,016	7,857	2,590	2,296	1,346	1,625
ViiV Healthcare (HIV)	353	153	145	25	30	565	245	232	40	48
<i>Combivir</i>	71	30	27	9	5	114	48	43	15	8
<i>Epivir</i>	26	11	9	3	3	42	18	14	5	5
<i>Epzicom/Kivexa</i>	140	51	65	7	17	224	82	104	11	27
<i>Lexiva</i>	32	17	12	1	2	51	27	19	2	3
<i>Selzentry</i>	23	10	12	-	1	37	16	19	-	2
<i>Trizivir</i>	30	15	13	-	2	48	24	21	-	3
	5,264					8,422				

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

Turnover

Consumer Healthcare

Three months ended 31st March 2011

	Total £m	Total \$m
Over-the-counter medicines	641	1,026
Oral healthcare	426	682
Nutritional healthcare	254	406
	<u>1,321</u>	<u>2,114</u>

	Total £m	Total \$m
USA	241	386
Europe	475	760
Rest of World	605	968
	<u>1,321</u>	<u>2,114</u>

Balance sheet

	31st March 2011 £m	31st March 2011 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	9,020	14,432
Goodwill	3,712	5,939
Other intangible assets	8,580	13,728
Investments in associates and joint ventures	637	1,019
Other investments	687	1,099
Deferred tax assets	2,514	4,022
Derivative financial instruments	93	149
Other non-current assets	534	855
Total non-current assets	25,777	41,243
Current assets		
Inventories	4,035	6,456
Current tax recoverable	51	82
Trade and other receivables	5,949	9,518
Derivative financial instruments	82	131
Liquid investments	170	272
Cash and cash equivalents	6,498	10,397
Assets held for sale	16	26
Total current assets	16,801	26,882
TOTAL ASSETS	42,578	68,125
LIABILITIES		
Current liabilities		
Short-term borrowings	(258)	(413)
Trade and other payables	(7,246)	(11,594)
Derivative financial instruments	(174)	(279)
Current tax payable	(1,604)	(2,566)
Short-term provisions	(3,829)	(6,126)
Total current liabilities	(13,111)	(20,978)
Non-current liabilities		
Long-term borrowings	(14,829)	(23,726)
Deferred tax liabilities	(732)	(1,171)
Pensions and other post-employment benefits	(2,608)	(4,173)
Other provisions	(784)	(1,255)
Derivative financial instruments	(5)	(8)
Other non-current liabilities	(622)	(995)
Total non-current liabilities	(19,580)	(31,328)
TOTAL LIABILITIES	(32,691)	(52,306)
NET ASSETS	9,887	15,819
EQUITY		
Share capital	1,416	2,266
Share premium account	1,435	2,296
Retained earnings	4,985	7,976
Other reserves	1,235	1,976
Shareholders' equity	9,071	14,514
Non-controlling interests	816	1,305
TOTAL EQUITY	9,887	15,819

US dollar amounts shown above are a convenience transaction of the sterling amounts using the period end rate of £1/\$1.60.